Alcon drops AMD candidate

Article

Following disappointing clinical trial results, Alcon has discontinued its plans to develop anecortave acetate for the prevention of choroidal neovascularization secondary to age-related macular degeneration (AMD).

Following disappointing clinical trial results, Alcon has discontinued its plans to develop anecortave acetate for the prevention of choroidal neovascularization secondary to age-related macular degeneration (AMD).

At the 24-month time point, the compound, which was tested in 2546 patients, had failed to achieve both primary and secondary endpoints, causing Alcon to discontinue four separate studies that were being conducted in the US and Asia.

Although Alcon will no longer study the efficacy of anecortave acetate in the treatment of AMD, the company plans to continue its study of the compound as an anterior juxtascleral depot for the reduction of intraocular pressure in open-angle glaucoma.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.